Winfield Associates’s ResMed RMD Stock Holding History

Winfield Associates’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5	Closed	–	–	872
2017 Q2	$0	Hold	5	–	–	﹤0.01%	905
2017 Q1	$0	Hold	5	–	–	﹤0.01%	787
2016 Q4	$0	Buy	+5	New	+$306	﹤0.01%	769

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Winfield Associates's RMD Position: Q3 2017 in Review

Winfield Associates sold out of ResMed (RMD) in Q3 2017, closing a stake of 5 shares.

Winfield Associates first reported a position in RMD in Q4 2016 and held it in 3 quarters. The position peaked at $0 in Q2 2017. 362 funds tracked by Wall St. Rank hold RMD as of Q3 2017.

Winfield Associates reported no remaining ResMed position as of Q3 2017 after selling out during the quarter.
Winfield Associates sold 5 ResMed shares in Q3 2017.
Winfield Associates first reported a position in ResMed in Q4 2016 and held it in 3 quarters.
Winfield Associates's ResMed position peaked at $0 in Q2 2017.
362 funds tracked by Wall St. Rank held ResMed as of Q3 2017.

Based on Winfield Associates's 13F filing for Q3 2017, filed 6 Nov 2017.